Polycystic Ovarian Syndrome

New polycystic ovarian syndrome research from H.F. Escobarmorreale et al outlined

Published in Women's Health Weekly, January 8th, 2009

"Osteoprotegerin (OPG), an inhibitor of osteoclastic bone resorption. has a variety of functions including anti-inflammatory effects and a possible cardiovascular protective role. Both low-grade chronic inflammation and cardiovascular risk are increased in women with the polycystic ovary syndrome (PCOS)," researchers in Madrid, Spain report.

"We aimed to study serum OPG concentrations in PCOS patients. Case-control study including 40 PCOS patients matched with 40 non-hyperandrogenic women for age and body mass index. Basal Serum sampling and standard oral glucose tolerance test, and measurement of serum OPG concentrations by commercial ELISA. Serum OPG concentrations...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2009-01-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry